<DOC>
	<DOCNO>NCT00655993</DOCNO>
	<brief_summary>Hypothesis pilot study simvastatin low level CRP ET-1 COPD patient .</brief_summary>
	<brief_title>Effect Statin Therapy C-Reactive Protein Levels Patients With Chronic Obstructive Lung Disease ( COPD )</brief_title>
	<detailed_description>Patients chronic obstructive lung disease ( COPD ) ongoing systemic inflammation , assess measure C-reactive protein ( CRP ) . CRP find strong independent predictor future COPD outcome . Statins class cholesterol lower drug decrease mortality cardiovascular disease stroke . In addition , anti-inflammatory , anti-thrombotic immunomodulatory property . Statins low C-reactive protein ability reduce production interleukin ( IL ) -6 , cytokine activates acute phase CRP response . Thus rationale study evaluate effect statin level CRP ET-1 COPD patient .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Medically optimize COPD patient Age 4079 year . serum CRP level &gt; 3mg/l Current smoker COPD exacerbation last 2 month . Active hepatic severe renal dysfunction . connective tissue disease , chronic inflammatory disease , malignancy , acute illness , leukocytosis ( &gt; 10,000 white blood cell ) thrombocytosis ( &gt; 450,000 platelet ) . Recent h/o myocardial infarction , angina last 6 month . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>COPD</keyword>
	<keyword>Inflammation</keyword>
	<keyword>CRP level</keyword>
	<keyword>simvastatin</keyword>
</DOC>